Too frail or not too frail? Prognosis and treatment options in older CLL patientsdoi:10.1007/s12254-025-01031-wChronic lymphocytic leukemia (CLL) is adisease that primarily affects older patients, with amedian age at diagnosis of 72years. Older patients, in this review defined as 80years or ...
Risk stratification and prognosis were evaluated by CLL-IPI scoring system. Results①Of the 215 patients, 143 were males and 72 were females, with a median age of 60 (16-85) years old. The median treatment-free survival (TFS) and overall survival (OS) was 16 months (4-24 months) and...
and modeling infection as an outcome, while necessary for the prediction of infections, was also somewhat predictive of CLL treatment (See Supplementary Fig.13for further evidence). Like ENS-TREAT, CLL-IPI was not predictive of infections prior to CLL treatment (Supplementary Fig.14a...
VIDEO: AI, big data may transform CLL treatment, prognosis More from this collection View All Video 1 03:56 Ryan W. Jacobs, MD VIDEO: Treatment options in CLL Video 2 01:24 Ryan W. Jacobs, MD VIDEO: Potential causes, risk factors for CLL ...
Before each line of therapy: we obtain FISH to assess for 17p deletion, 11q deletion, 13q deletion, and trisomy 12, before each line of therapy, as presence of 17p deletion can influence treatment selection (Section 4.4; Figure 1C). Although an 11q deletion carried a negative prognosis ...
Although these patients have a poor prognosis and there is no clear standard of care, the National Comprehensive Cancer Network (NCCN) guidelines list the following as preferred regimens for first-line treatment[12]: Acalabrutinib with or without obinutuzumab ...
In the end, a precise definition of fitness based on scores of geriatric and/or comorbidity tests will be difficult to achieve, since prognosis and treatment-related toxicity differ from disease to disease, and as such, the criteria to define fit, vulnerable and terminally ill patients also vari...
It was found that, compared to blank (wild type, no treatment) or negative controls (NC-siRNA), Kaiso mRNA was significantly reduced 48, 60, and 72 h after Kaiso-siRNA transfection. The least mRNA was at 48 h after transfection (Fig. 2A and D and Supplementary Figure S2). ...
EP: 4.Clinical Insights: Exploring Combination Regimens in First-Line Treatment in CLL: SEQUOIA Arm D and BOVen Trials EP: 5.Key Takeaways From the AMPLIFY Trial at ASH 2024: Fixed-Duration Acalabrutinib Plus Venetoclax With or Without Obinutuzumab vs Chemoimmunotherapy in...
EP: 4.Clinical Insights: Exploring Combination Regimens in First-Line Treatment in CLL: SEQUOIA Arm D and BOVen Trials EP: 5.Key Takeaways From the AMPLIFY Trial at ASH 2024: Fixed-Duration Acalabrutinib Plus Venetoclax With or Without Obinutuzumab vs Chemoimmunotherapy in T...